Gilead Sciences, Inc. $GILD Shares Acquired by Ieq Capital LLC

Ieq Capital LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 375.7% in the third quarter, Holdings Channel.com reports. The institutional investor owned 160,503 shares of the biopharmaceutical company’s stock after purchasing an additional 126,764 shares during the quarter. Ieq Capital LLC’s holdings in Gilead Sciences were worth $23,923,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of GILD. BlackRock Inc. bought a new position in Gilead Sciences in the second quarter worth about $15,393,785,000. State Street Corp boosted its stake in Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after acquiring an additional 1,357,967 shares during the period. Amundi boosted its stake in Gilead Sciences by 10.7% in the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after acquiring an additional 1,018,976 shares during the period. Legal & General Group Plc acquired a new position in Gilead Sciences in the second quarter valued at approximately $1,316,606,000. Finally, Deutsche Bank AG bought a new position in shares of Gilead Sciences during the second quarter valued at approximately $918,387,000. Institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Wettan Keeley M. Cain sold 3,399 shares of the company’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $164.11, for a total value of $557,809.89. Following the completion of the sale, the executive vice president owned 5,360 shares of the company’s stock, valued at $879,629.60. This represents a 38.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $170.55, for a total transaction of $4,775,400.00. Following the transaction, the insider owned 110,684 shares in the company, valued at $18,877,156.20. This represents a 20.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 237,709 shares of company stock valued at $39,799,137 over the last three months. 0.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GILD. TD Cowen set a $175.00 price target on Gilead Sciences in a research report on Wednesday. Sanford C. Bernstein reissued an “outperform” rating and issued a $175.00 price target on shares of Gilead Sciences in a report on Monday, November 2nd. Cantor Fitzgerald boosted their price objective on Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Finally, Bank of America upped their price objective on Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research note on Tuesday, October 20th. Twenty-three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $171.63.

Read Our Latest Stock Analysis on Gilead Sciences

Gilead Sciences Trading Down 1.4%

Shares of NASDAQ:GILD opened at $166.53 on Friday. The company has a market cap of $206.55 billion, a PE ratio of -52.70 and a beta of 0.35. The company’s 50-day moving average price is $156.80 and its 200 day moving average price is $142.34. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. During the same period in the previous year, the business posted $2.47 EPS. Gilead Sciences’s revenue was up 6.8% on a year-over-year basis. Sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.97 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. Gilead Sciences’s dividend payout ratio is presently -103.80%.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.